SCHEMBL10116191

SCHEMBL10116191

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.66
RAB9A P51151 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
MAPT P10636 2/20 0.58
HSD17B10 Q99714 1/20 0.58
ENPP3 O14638 4/20 0.55
ENPP1 P22413 4/20 0.55
PRMT1 Q99873 1/20 0.55
NT5E P21589 1/20 0.53
MAPK1 P28482 1/20 0.53
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
CA1 P00915 2/20 0.52
CA12 O43570 1/20 0.52
CA9 Q16790 1/20 0.52
ENPP2 Q13822 2/20 0.51
HTT P42858 1/20 0.51
NAMPT P43490 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116240 0.92 MEN1 (0.55) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116182 0.87 KMT2A (0.57) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116183 0.87 NPC1 (0.67) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116194 0.87 MEN1 (0.65) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116238 0.87 KDM4E (0.65) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116190 0.86 LMNA (0.72) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116235 0.85 MEN1 (0.52) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10114513 0.85 MEN1 (0.61) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116397 0.85 KMT2A (0.49) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL10116221 0.85 ADORA3 (0.64) NPC1RAB9ASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R NPC1 1435/4885RAB9A 3699/4885SMN1; SMN2 2213/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1353/4885RAB9A 3651/4885SMN1; SMN2 2197/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R NPC1 1462/4885RAB9A 3820/4885SMN1; SMN2 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.